New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of Hospitalizations Due to Heart Failure in Patients with Corona
07 Februar 2007 - 8:52PM
PR Newswire (US)
- - - NEW YORK, Feb. 7 /PRNewswire-FirstCall/ -- Patients with
coronary heart disease who took Lipitor(R) (atorvastatin calcium)
80 mg tablets reduced their risk of hospitalizations due to heart
failure compared to patients taking the 10 mg dose of Lipitor,
according to a new analysis of a subset of patients from the
five-year TNT (Treating to New Targets) study, published in today's
issue of Circulation. "These results show that patients with a
history of heart failure who were treated with Lipitor 80 mg dose
significantly reduced their chances of hospitalizations for heart
failure," said Dr. Rochelle Chaiken, vice president of Pfizer's CV
Metabolic group. "This important new information for physicians and
patients adds to what has been shown about the cardiovascular
efficacy of Lipitor in reducing the risk of events like heart
attacks, strokes and revascularization procedures." The analysis
showed that patients with heart disease who took Lipitor 80 mg dose
achieved significant reductions in the risk of hospitalizations due
to heart failure by 26 percent. For those patients with a history
of heart failure, Lipitor 80 mg significantly reduced their risk of
hospitalization by 41 percent. "These findings have important
implications for the management of these high-risk patients," said
Dr. David Waters, professor of medicine at the University of
California, San Francisco. "Hospitalizations due to heart failure
are a major contributor to growing healthcare costs in the United
States." Heart failure is the leading cause of hospitalization for
adults over 65 in the United States. Patients hospitalized once for
heart failure face a substantially greater risk of being
hospitalized for the condition again and a greater risk of death.
The estimated total cost of heart failure in 2007 in the United
States is $33.2 billion ($30.2 billion direct and $3 billion
indirect costs). Impact of Heart Failure Heart failure is a
condition that occurs when the heart muscle cannot pump enough
blood to keep up with the body's needs. Nearly 5 million Americans
and 6.5 million Europeans live with heart failure, and nearly 1
million new cases are diagnosed each year worldwide. Patients who
develop heart failure often have other health conditions or
behaviors that affect how the heart works, such as damage from a
heart attack, having high blood pressure, smoking, being
overweight, eating foods high in fat and cholesterol, not
exercising and having diabetes. Of the 10,000 patients in the
overall TNT study: * The incidence of hospitalizations due to heart
failure was 2.4 percent in patients who took Lipitor 80 mg dose and
3.3 percent in patients who took Lipitor 10 mg dose. Sub analyses
of these patients showed: * Among those with a history of heart
failure (781 patients), the incidence of hospitalizations for heart
failure was 10.6 percent in patients who took Lipitor 80 mg
compared to 17.3 percent in patients who took the 10 mg dose. * In
patients without a history of heart failure, the rates of
hospitalization due to heart failure were lower compared to those
with a history of heart failure (1.8 percent for patients who took
the 80 mg dose versus 2.0 percent for patients who took the 10 mg
dose). The difference between treatment groups was not
statistically significant. About TNT (Treating to New Targets)
Study The TNT study was a landmark investigator-led trial
coordinated by an independent steering committee and sponsored by
Pfizer. It was the largest study to date evaluating the efficacy
and safety of Lipitor 80 mg. The study enrolled 10,001 men and
women with coronary heart disease aged 35 years to 75 years in 14
countries and followed them for an average of five years. About
Lipitor Lipitor is supported by an extensive clinical trial program
involving more than 400 ongoing and completed trials with more than
80,000 patients. Important US Prescribing Information Lipitor is a
prescription medication. It is used in patients with multiple risk
factors for heart disease such as family history, high blood
pressure, age, low HDL ("good" cholesterol) or smoking to reduce
the risk of heart attack and stroke. When diet and exercise alone
are not enough, Lipitor is used along with a low-fat diet and
exercise to lower cholesterol. Lipitor is also used in patients
with type 2 diabetes and at least one other risk factor for heart
disease such as high blood pressure, smoking or complications of
diabetes, including eye disease and protein in urine, to reduce the
risk of heart attack and stroke. Lipitor is not for everyone. It is
not for those with liver problems. And it is not for women who are
nursing, pregnant or may become pregnant. Patients taking Lipitor
should tell their doctors if they feel any new muscle pain or
weakness. This could be a sign of rare but serious muscle side
effects. Patients should tell their doctors about all medications
they take. This may help avoid serious drug interactions. Doctors
should do blood tests to check liver function before and during
treatment and may adjust the dose. The most common side effects are
gas, constipation, stomach pain and heartburn. They tend to be mild
and often go away. For additional product information, visit
http://www.lipitor.com/. DATASOURCE: Pfizer Inc CONTACT: Vanessa
Aristide, +1-212-733-3784 Web site: http://www.pfizer.com/
http://www.lipitor.com/ Company News On-Call: Pfizer's press
releases are available through PR Newswire's Company News On-Call
service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Copyright